类风湿关节炎患者启用生物制剂改善病情抗风湿药后急性冠脉综合征的短期、中期与长期风险:四国队列研究结果
这项观察性队列研究纳入丹麦、芬兰、挪威和瑞典2008至2017年启用bDMARD的24083例类风湿关节炎患者,比较1年、2年和5年急性冠脉综合征(ACS)发生率。RA患者总体ACS发生率比一般人群高80%,各bDMARD之间风险差异很小,仅5年风险窗内阿巴西普、英夫利西单抗和利妥昔单抗出现信号。
要点
- RA患者启用bDMARD后ACS发生率较一般人群高80%。
- 各bDMARD短期、中期和长期ACS风险差异很小,以依那西普为参照的HR接近1。
- 仅5年风险窗内阿巴西普、英夫利西单抗和利妥昔单抗出现信号。
核心结论
- RA患者启用bDMARD后ACS发生率仍高于一般人群。
- 在常规诊疗中,各bDMARD的短期、中期和长期ACS风险差异很小。
研究设计与样本
- 观察性队列研究,纳入丹麦、芬兰、挪威和瑞典2008至2017年启用bDMARD的患者。
- 共24083例患者(75%为女性,平均年龄56岁),贡献40850个治疗疗程。
- 通过登记链接识别首次ACS时间,计算1年、2年和5年发生率(用药期间及自治疗开始以来),并用Cox回归(HR)比较各治疗ACS发生率,同时考虑ACS危险因素。
- 按年龄、既往bDMARD数量和心血管疾病史定义亚组分别分析,并与个体匹配的一般人群队列比较。
主要发现
- 最长(5年)随访期间共141257人年,发生780例ACS事件(粗发生率5.5/1000人年)。
- RA患者总体ACS发生率比一般人群高80%。
- 所有bDMARD和随访定义下,以依那西普为参照的HR均接近1,例外是5年风险窗内阿巴西普、英夫利西单抗和利妥昔单抗出现信号。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To compare the 1-year, 2-year and 5-year incidences of acute coronary syndrome (ACS) in patients with rheumatoid arthritis (RA) starting any of the biologic disease-modifying antirheumatic drugs (bDMARDs) currently available in clinical practice and to anchor these results with a general population comparator. METHODS: Observational cohort study, with patients from Denmark, Finland, Norway and Sweden starting a bDMARD during 2008-2017. Time to first ACS was identified through register linkages. We calculated the 1-year, 2-year and 5-year incidence rates (IR) (on drug and ever since treatment start) and used Cox regression (HRs) to compare ACS incidences across treatments taking ACS risk factors into account. Analyses were further performed separately in subgroups defined by age, number of previous bDMARDs and history of cardiovascular disease. We also compared ACS incidences to an individually matched general population cohort. RESULTS: 24 083 patients (75% women, mean age 56 years) contributing 40 850 treatment courses were included. During the maximum (5 years) follow-up (141 257 person-years (pyrs)), 780 ACS events occurred (crude IR 5.5 per 1000 pyrs). Overall, the incidence of ACS in RA was 80% higher than that in the general population. For all bDMARDs and follow-up definitions, HRs were close to 1 (etanercept as reference) with the exception of the 5-year risk window, where signals for abatacept, infliximab and rituximab were noted. CONCLUSION: The rate of ACS among patients with RA initiating bDMARDs remains elevated compared with the general population. As used in routine care, the short-term, intermediate-term and longer-term risks of ACS vary little across individual bDMARDs.
引用
- Delcoigne B, Ljung L, Provan SA, et al. Short-term, intermediate-term and long-term risks of acute coronary syndrome in cohorts of patients with RA starting biologic DMARDs: results from four Nordic countries. Ann Rheum Dis. 2022. PMID: 35318218. doi:10.1136/annrheumdis-2021-221996
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。